BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCTX BriaCell Therapeutics Corp.

Post-Market Trading 11-26 19:26:21 EST

0.7471

+0.0661

+9.71%

盘后0.7379

-0.0092-1.23%

19:21 EST

High0.7490	Low0.6614	Vol2.55M
Open0.7150	D1 Closing0.6810	Amplitude12.86%
Mkt Cap26.77M	Tradable Cap23.39M	Total Shares35.84M
T/O1.86M	T/O Rate8.15%	Tradable Shares31.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BCTX","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp.","latestPrice":0.7471,"timestamp":1732654800000,"preClose":0.681,"halted":0,"volume":2551546,"hourTrading":{"tag":"盘后","latestPrice":0.7379,"preClose":0.7471,"latestTime":"19:21 EST","volume":5226,"amount":3800.6803575,"timestamp":1732666881909},"delay":0,"floatShares":31307088,"shares":35838161,"eps":-0.291187,"marketStatus":"Post-Market Trading","change":0.0661,"latestTime":"11-26 19:26:21 EST","open":0.715,"high":0.749,"low":0.661401,"amount":1860095.9154404,"amplitude":0.128633,"askPrice":0.7471,"askSize":34,"bidPrice":0.67,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.291187,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732669200000},"marketStatusCode":4,"adr":0,"listingDate":1614142800000,"exchange":"NASDAQ","adjPreClose":0.681,"preHourTrading":{"tag":"盘前","latestPrice":0.7,"preClose":0.681,"latestTime":"09:29 EST","volume":840164,"amount":626316.3849488001,"timestamp":1732631366365},"postHourTrading":{"tag":"盘后","latestPrice":0.7379,"preClose":0.7471,"latestTime":"19:21 EST","volume":5226,"amount":3800.6803575,"timestamp":1732666881909},"volumeRatio":1.83472,"impliedVol":1.6361,"impliedVolPercentile":0.6996},"requestUrl":"/m/hq/s/BCTX/wiki","defaultTab":"wiki","newsList":[{"id":"2486302005","title":"BriaCell Highlights Promising Breast Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2486302005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486302005?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:48","pubTimestamp":1732628910,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics has announced promising results from their Phase 2 clinical trial, sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-highlights-promising-breast-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-highlights-promising-breast-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2486077856","title":"BriaCell to highlight OS, clinical benefit data of Bria-IMT in MBC patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2486077856","media":"TIPRANKS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486077856?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:55","pubTimestamp":1732625708,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics will be highlighting its overall survival and clinical benefit data in metastatic breast cancer patients including tho...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-to-highlight-os-clinical-benefit-data-of-bria-imt-in-mbc-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-to-highlight-os-clinical-benefit-data-of-bria-imt-in-mbc-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX","MBC","BK4086"],"gpt_icon":0},{"id":"2486077540","title":"BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2486077540","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486077540?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:50","pubTimestamp":1732625400,"startTime":"0","endTime":"0","summary":"SABCS “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes. Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calculation is pending, as many patients remain alive. Five poster presentations to feature increased presence of cancer fighting CD8+ “killer” T cell in metastatic breast cancer tumors, response in central nervous system  metastases and additional Bria-IMT clinical data from the Phase 2 trial of Bria-IMT + immune check point inhibitor in metastatic breast cancer. Collaboration with the Medical College of Wisconsin will investigate use of Bria-IMT + CPI in any cancer patient with central nervous system  metastases","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-2024-sabcs-spotlight-poster-125000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DTH","CPI","MBC","BK4097","OS","BK4086","BK4139","BK4135","BCTXW","CNS","BCTX"],"gpt_icon":0},{"id":"2486862260","title":"BriaCell director Marc Lustig resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2486862260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486862260?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:55","pubTimestamp":1732539313,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics announces that it has accepted the resignation of Mr. Marc Lustig, MSc, MBA from the Board of Directors. Published fir...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-director-marc-lustig-resigns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-director-marc-lustig-resigns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2486086954","title":"BriaCell Provides Update to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2486086954","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486086954?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:50","pubTimestamp":1732539000,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov.  25, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/25/2986614/0/en/BriaCell-Provides-Update-to-its-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2485249542","title":"BriaCell Advances Cancer Treatment with New Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485249542?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:13","pubTimestamp":1732194823,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics has dosed its first patient in a Phase 1/2 trial to test its innovati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-advances-cancer-treatment-with-new-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-advances-cancer-treatment-with-new-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2485493556","title":"BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2485493556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485493556?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:50","pubTimestamp":1732193400,"startTime":"0","endTime":"0","summary":"Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic breast cancerBria-OTS to be studied as monotherapy and in combination with Bei","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985129/0/en/BriaCell-Announces-First-Patient-Dosed-with-Bria-OTS-in-Metastatic-Breast-Cancer-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139"],"gpt_icon":1},{"id":"2481776181","title":"BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481776181","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481776181?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:50","pubTimestamp":1731070200,"startTime":"0","endTime":"0","summary":"BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+) and prostate cancer (Bria-PROS+) generate robust anti-cancer activity in preclinical modelsNovel therapy activates both in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/08/2977589/0/en/BriaCell-Showcases-Robust-Anti-Cancer-Activity-of-Personalized-Off-the-Shelf-Immunotherapy-Pipeline-at-the-2024-SITC-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1541","IE00B12V2V27.USD","BK4139","IE00BYTNYN87.SGD","SG9999011746.SGD","BK4080","BK1103","BK4231","IE00BYQNZ168.SGD","SITC","BCTX","01308"],"gpt_icon":0},{"id":"2480307961","title":"BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2480307961","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480307961?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:50","pubTimestamp":1730724600,"startTime":"0","endTime":"0","summary":"Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT plus immune check point inhibitor in metastatic breast cancerPresentations includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2973985/0/en/BriaCell-Overall-Survival-Data-Selected-for-Spotlight-Poster-at-2024-San-Antonio-Breast-Cancer-Symposium-December-10-13.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","CNS","BCTX"],"gpt_icon":0},{"id":"2480857183","title":"BriaCell Therapeutics Faces Uncertain Financial Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2480857183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480857183?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:28","pubTimestamp":1730492909,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics ( ($TSE:BCT) ) has shared an update. BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics, has filed its consoli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-faces-uncertain-financial-future?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-faces-uncertain-financial-future?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BCTX","BK4139"],"gpt_icon":0},{"id":"2479183674","title":"Briacell Therapeutics Corp reports results for the quarter ended in July 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2479183674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479183674?lang=en_us&edition=fundamental","pubTime":"2024-10-29 10:26","pubTimestamp":1730168789,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp reports results for the quarter ended in July 31 - Earnings Summary  Briacell Therapeutics Corp BCT.TO reported a quarterly adjusted loss of 7 cents per share for the quarte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nL8N3M5020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX"],"gpt_icon":0},{"id":"2477362708","title":"BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2477362708","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477362708?lang=en_us&edition=fundamental","pubTime":"2024-10-23 02:54","pubTimestamp":1729623280,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics' lead candidate, Bria-IMT, shows promising trial results for metastatic breast cancer, potentially doubling overall survival and median progression-free survival.Despite a market","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344723885/image_1344723885.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344723885/image_1344723885.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4728383-briacell-high-potential-in-phase-3-breast-cancer-financing-concerns","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BCTX","BCTXW"],"gpt_icon":1},{"id":"2477600352","title":"BriaCell Higher as it Reports \"Standard-Beating\" Survival Data From Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2477600352","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477600352?lang=en_us&edition=fundamental","pubTime":"2024-10-22 23:06","pubTimestamp":1729609616,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  was last seen up 3.6% after the company on Tuesday released new positive data in its Phase 2 metastatic breast cancer  study.In the study, patients treated with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% . This rate exceeds the survival data of the current standard of care for similar patients. Four of the 13 patients recruited in 2022 remain in survival follow-up.\"With over 40,000 deaths each year in the US alone, late-stage MBC remains an important unmet medical need for many patients and their families. Approved treatments are restricted by poor survival and harsh side effects,\" said Adam Brufsky, Professor of Medicine at the University of Pittsburgh School of Medicine. \"We are impressed with BriaCell's promising randomized Phase 2 survival data indicating robust survival and a preferred tolerability profile for Bria-IMT and look forward to seeing the data being replicated i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-higher-reports-standard-beating-150656119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4124","MBC","SMP","BK4139","BCTX","BK4086","BCTXW"],"gpt_icon":0},{"id":"2477699338","title":"BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2477699338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477699338?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:50","pubTimestamp":1729597800,"startTime":"0","endTime":"0","summary":"55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients. Multiple outperforming patients with overall survival of over 2 years. Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors  and/or antibody-drug conjugates . Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive. In BriaCell’s Phase 2 clinical study, patients treated with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% . This rate exceeds the survival data of the current standard of care for similar patients . Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well, including:. “A number of patients with metastatic breast cancer have disease progression on currently approved drugs, including ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-reports-outperforming-metastatic-breast-115000248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTXW","BCTX","SMP"],"gpt_icon":0},{"id":"2475663132","title":"BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2475663132","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475663132?lang=en_us&edition=fundamental","pubTime":"2024-10-15 23:49","pubTimestamp":1729007358,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said Tuesday that patient enrollment for its pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer is on track for expected completion by mid-2025.The trial aims to enroll up to 354 patients, randomized 1:1 to receive either the BriaCell regimen or physician's choice, with a subset of 50 patients receiving Bria-IMT monotherapy, the company said.BriaCell Therapeutics shares rose more than 6% in recent trading.Price: 0.95, Change: +0.06, Percent Change: +6.22","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2475468023","title":"BriaCell gains after update on late-stage trial for lead asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2475468023","media":"seekingalpha","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475468023?lang=en_us&edition=fundamental","pubTime":"2024-10-15 22:52","pubTimestamp":1729003928,"startTime":"0","endTime":"0","summary":"luismmolina/E+ via Getty Images  Shares of BriaCell Therapeutics (NASDAQ:BCTX) spiked in the morning hours on Tuesday after the Canadian biotech said that patient enrollment in its Phase 3 pivotal trial for lead candidate Bria-IMT in breast cancer is on track for completion by","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1317832692/image_1317832692.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1317832692/image_1317832692.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4160766-briacell-stock-gains-after-trial-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BCTX","QLD","PSQ","TQQQ","NQmain","BK4139",".IXIC","QID","MNQmain","SQQQ"],"gpt_icon":0},{"id":"2475570198","title":"BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2475570198","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475570198?lang=en_us&edition=fundamental","pubTime":"2024-10-15 19:50","pubTimestamp":1728993000,"startTime":"0","endTime":"0","summary":"35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT combination with immune check point inhibitor in metastatic breast cancer . Primary endpoint is overall survival  with Bria-IMT regimen plus Check Point Inhibitor  vs treatment of physician’s choice. Interim data analysis planned at 144 events  could provide full approval and marketing authorization. Pivotal Phase 3 study patient enrollment completion is expected in mid-2025. No serious adverse events related to Bria-IMT have been reported to date. Interim data will be analyzed once 144 events  occur, comparing the overall survival  in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. Secondary analyses include comparison of the Bria-IMT combination regimen vs Bria-IMT monotherapy. BriaCell recently announced impre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-provides-phase-3-clinical-115000166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OS","CPI","BCTX","BK4086","MBC","BCTXW","BK4097"],"gpt_icon":1},{"id":"2472845699","title":"BriaCell Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2472845699","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472845699?lang=en_us&edition=fundamental","pubTime":"2024-10-03 19:12","pubTimestamp":1727953920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 03, 2024 07:12 ET (11:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","LENZ"],"gpt_icon":0},{"id":"2472969310","title":"BriaCell’s Bria-IMT Regimen Shows Promise for Metastatic Breast Cancer with Brain Metastasis: A Buy Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2472969310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472969310?lang=en_us&edition=fundamental","pubTime":"2024-10-03 18:17","pubTimestamp":1727950651,"startTime":"0","endTime":"0","summary":"Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on BriaCell Therapeutics (BCT – Research Report). The associated price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/briacells-bria-imt-regimen-shows-promise-for-metastatic-breast-cancer-with-brain-metastasis-a-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/briacells-bria-imt-regimen-shows-promise-for-metastatic-breast-cancer-with-brain-metastasis-a-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2472500799","title":"BriaCell Therapeutics Closes Offering of 5.13 Million Shares, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2472500799","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472500799?lang=en_us&edition=fundamental","pubTime":"2024-10-03 05:46","pubTimestamp":1727905595,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said it closed an offering of about 5.13 million shares and warrants at a combined price of $0.975 per share and associated warrant, targeting gross proceeds of about $5 million.The warrants are for purchasing up to about 5.13 million shares, the company said late Wednesday. They have an exercise price of $0.85 per share and are immediately exercisable upon issuance for five years.BriaCell intends to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives.Shares of the company fell 5% in after-hours activity.Price: 0.9599, Change: -0.0501, Percent Change: -4.96","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BCTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://briacell.com","stockEarnings":[{"period":"1week","weight":0.1445},{"period":"1month","weight":-0.2145},{"period":"3month","weight":-0.1589},{"period":"6month","weight":-0.5578},{"period":"1year","weight":-0.8635},{"period":"ytd","weight":-0.8836}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.059743},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.002131},{"month":3,"riseRate":0.75,"avgChangeRate":0.085777},{"month":4,"riseRate":0,"avgChangeRate":-0.150063},{"month":5,"riseRate":0,"avgChangeRate":-0.204537},{"month":6,"riseRate":0.75,"avgChangeRate":0.134713},{"month":7,"riseRate":0.5,"avgChangeRate":-0.054561},{"month":8,"riseRate":1,"avgChangeRate":0.163345},{"month":9,"riseRate":0.5,"avgChangeRate":0.089973},{"month":10,"riseRate":0,"avgChangeRate":-0.176016},{"month":11,"riseRate":0.5,"avgChangeRate":0.07406},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.079632}],"exchange":"NASDAQ","name":"BriaCell Therapeutics Corp.","nameEN":"BriaCell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BriaCell Therapeutics Corp.,BCTX,BriaCell Therapeutics Corp.股票,BriaCell Therapeutics Corp.股票老虎,BriaCell Therapeutics Corp.股票老虎国际,BriaCell Therapeutics Corp.行情,BriaCell Therapeutics Corp.股票行情,BriaCell Therapeutics Corp.股价,BriaCell Therapeutics Corp.股市,BriaCell Therapeutics Corp.股票价格,BriaCell Therapeutics Corp.股票交易,BriaCell Therapeutics Corp.股票购买,BriaCell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}